P. Fleck

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller et al. · New England Journal of Medicine · 2013 · 2.5K citations · Full text

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman et al. · The Lancet · 2015 · 748 citations

Diabetes Management, Heart Failure, Alogliptin Versus Placebo +11

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

Ralph A. DeFronzo, P. Fleck, Craig Wilson et al. · Diabetes Care · 2008 · 224 citations · Full text

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Michael A. Nauck, Graham C. Ellis, P. Fleck et al. · International Journal of Clinical Practice · 2008 · 203 citations · Full text

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA _1c without causing weight gain or increased hypoglycaemia

Julio Rosenstock, Marc Rendell, Jorge Luiz Gross et al. · Diabetes Obesity and Metabolism · 2009 · 188 citations